Canada
· Delayed Price · Currency is CAD BioHarvest Sciences Statistics
Total Valuation
BioHarvest Sciences has a market cap or net worth of CAD 151.96 million. The enterprise value is 162.68 million.
| Market Cap | 151.96M |
| Enterprise Value | 162.68M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioHarvest Sciences has 17.33 million shares outstanding. The number of shares has increased by 16.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 17.33M |
| Shares Change (YoY) | +16.41% |
| Shares Change (QoQ) | +6.07% |
| Owned by Insiders (%) | 19.29% |
| Owned by Institutions (%) | n/a |
| Float | 12.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.45 |
| PB Ratio | 27.18 |
| P/TBV Ratio | 27.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.00 |
| EV / Sales | 5.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.02 |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 2.58.
| Current Ratio | 0.80 |
| Quick Ratio | 0.48 |
| Debt / Equity | 2.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.07 |
| Interest Coverage | -1.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.95% |
| Return on Capital (ROIC) | -53.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.23 |
| Inventory Turnover | 3.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +18.27% |
| 50-Day Moving Average | 7.96 |
| 200-Day Moving Average | 8.23 |
| Relative Strength Index (RSI) | 56.46 |
| Average Volume (20 Days) | 2,056 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioHarvest Sciences had revenue of CAD 30.30 million and -23.23 million in losses. Loss per share was -1.51.
| Revenue | 30.30M |
| Gross Profit | 16.36M |
| Operating Income | -10.61M |
| Pretax Income | -23.23M |
| Net Income | -23.23M |
| EBITDA | -9.69M |
| EBIT | -10.61M |
| Loss Per Share | -1.51 |
Balance Sheet
The company has 3.74 million in cash and 14.45 million in debt, giving a net cash position of -10.71 million or -0.62 per share.
| Cash & Cash Equivalents | 3.74M |
| Total Debt | 14.45M |
| Net Cash | -10.71M |
| Net Cash Per Share | -0.62 |
| Equity (Book Value) | 5.59M |
| Book Value Per Share | 0.32 |
| Working Capital | -2.63M |
Cash Flow
In the last 12 months, operating cash flow was -9.85 million and capital expenditures -3.69 million, giving a free cash flow of -13.54 million.
| Operating Cash Flow | -9.85M |
| Capital Expenditures | -3.69M |
| Free Cash Flow | -13.54M |
| FCF Per Share | -0.78 |
Margins
Gross margin is 54.00%, with operating and profit margins of -35.00% and -76.65%.
| Gross Margin | 54.00% |
| Operating Margin | -35.00% |
| Pretax Margin | -76.65% |
| Profit Margin | -76.65% |
| EBITDA Margin | -31.99% |
| EBIT Margin | -35.00% |
| FCF Margin | n/a |
Dividends & Yields
BioHarvest Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.41% |
| Shareholder Yield | -16.41% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on June 3, 2024. It was a reverse split with a ratio of 0.0285714.
| Last Split Date | Jun 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0285714 |
Scores
BioHarvest Sciences has an Altman Z-Score of -2.89. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.89 |
| Piotroski F-Score | n/a |